Trials / Active Not Recruiting
Active Not RecruitingNCT02333760
Long Term Safety Follow up of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome
Long Term Safety Follow up of Patients Enrolled in the Phase I/II Clinical Trial of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome (GTG002-07 and GTG003-08).
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Genethon · Academic / Other
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
An open follow up study of patients enrolled in the Phase 1/2 clinical trial of haematopoietic stem cell gene therapy for the Wiskott-Aldrich Syndrome and treated with autologous CD34+ cells transduced with the w1.6\_hWASP\_WPRE (VSVg) lentiviral vector.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | Autologous CD34+ cells transduced with WASP lentiviral vector | Follow up of ex vivo gene therapy transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WASP gene |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2032-10-01
- Completion
- 2032-10-01
- First posted
- 2015-01-07
- Last updated
- 2021-06-03
Locations
2 sites across 2 countries: France, United Kingdom
Source: ClinicalTrials.gov record NCT02333760. Inclusion in this directory is not an endorsement.